Telix Pharmaceuticals Ltd 2024 SR
The report outlines Telix Pharmaceuticals' sustainability strategy focused on five pillars: Purpose, People, Principles, Performance, and Planet. In 2024, the company elevated Access to Medicine and Climate Strategy to highest priority status following a materiality assessment update. Key initiatives include the establishment of Rhine Pharma to expand global access to radiopharmaceuticals and the implementation of systems to track Scope 1 and Scope 2 emissions. The company also reported progress in diversity, with women representing 51% of the global workforce and 40% of non-executive directors.
Company: Telix Pharmaceuticals Ltd
Sector: Health Care
Country: Australia
Year: 2024
Type: SR
Pages: 10
Telix Pharmaceuticals Ltd
Sustainability Report
The report outlines Telix Pharmaceuticals' sustainability strategy focused on five pillars: Purpose, People, Principles, Performance, and Planet. In 2024, the company elevated Access to Medicine and Climate Strategy to highest priority status following a materiality assessment update. Key initiatives include the establishment of Rhine Pharma to expand global access to radiopharmaceuticals and the implementation of systems to track Scope 1 and Scope 2 emissions. The company also reported progress in diversity, with women representing 51% of the global workforce and 40% of non-executive directors.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
2024
Fiscal Year
2024
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Women in Management